As a cytotoxic therapy, LRT potently induced a threefold reduction of TC-1 tumor cell counts (tumor cells/mg tumor, Fig. 3a), and increased the fraction of apoptotic tumor cells, characterized by the expression of CC3 (Fig. 3b) and the death receptor Fas (Fig. 3c), when compared to control or E7 RNA-LPX vaccinated mice alone. This evidence concerns the gene FAS and neoplasm.